ESMO Abstract Leak Reveals Promising NSCLC Therapies from BMS, BeiGene, J & J, Mirati
Pictured: Illustration of a tumor in the lungs/iStock, Mohammed Haneefa Nizamudeen Following an embargo breach, the organizers of the upcoming European Society for Medical Oncology Congress 2023 on Tuesday made available all late-breaking abstracts to be presented during the meeting. The decision…#nsclc #bristolmyerssquibb #opdivo #johnsonjohnson #astrazeneca #tagrisso #biospace #spain #bms #checkmate (Source: Reuters: Health)
Source: Reuters: Health - October 19, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Media News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
The approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Pembrolizumab Wins FDA Approval in Operable Lung Cancer
(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) on Monday in combination with platinum-based chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC).
Approval was based on improved event-free... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 17, 2023 Category: Hematology Source Type: news
FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumors ≥4 cm or node positive) non-sm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
PET tracer targets KRAS mutations in cancer patients
In this study, the researchers tested the tracer in mice, and then for the first time in humans. They enrolled eight patients with lung cancer and six with colon cancer with KRAS mutations. Patients were injected with the tracer and then underwent hybrid PET/CT imaging.According to the findings, F-18 PFPMD-PET showed varied uptake in KRAS mutation tumors, and the SUVmax (uptake of the tracer by tumors) was significantly higher than in non-KRAS mutation tumors.In addition, the tracer uptake increase was generally consistent between the patients (+56.1%) and animal (+59.1%) studies, indicating that F-18 PFPMD is highly selec...
Source: AuntMinnie.com Headlines - October 16, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With Resectable NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Single Agent as Adjuvant Treatment After Surgery
RAHWAY, N.J.--(BUSINESS WIRE) October 16, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda , Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 16, 2023 Category: Drugs & Pharmacology Source Type: news
Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer
Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence. The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday. Pfizer…#pfizer #fda #nsclc #novartis #braf #xalkori #vizimproforegfr #pharos #braftovi #mektovi (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2023 Category: Consumer Health News Source Type: news
FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLC FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLC
The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 12, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC
(MedPage Today) -- The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on Wednesday.
The approval was... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 12, 2023 Category: Hematology Source Type: news
ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC ESMO 2023: Looking Forward to Fresh Data for Advanced NSCLC
Julia Rotow, MD, unpacks the cluster of new data regarding advanced non-small cell lung cancer to be presented at ESMO 2023, emphasizing developments regarding cancers with driver mutations.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
U.S. FDA approves Pfizer & #039;s BRAFTOVI ® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Source: World Pharma News)
Source: World Pharma News - October 12, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
